$ZyVersa Therapeutics (ZVSA.US)$ "The anticipation of an Inv...
$ZyVersa Therapeutics(ZVSA.US$ "The anticipation of an Investigational New Drug (IND) filing for IC 100 in 2024 further supports the positive outlook, marking a major milestone for the program.
Additionally, Arce’s confidence is backed by the near-term initiation of a Phase 2a trial of another ZyVersa candidate, VAR 200, in patients with diabetic kidney disease, which represents a significant step forward for the company.
Additionally, Arce’s confidence is backed by the near-term initiation of a Phase 2a trial of another ZyVersa candidate, VAR 200, in patients with diabetic kidney disease, which represents a significant step forward for the company.
These milestones affirmed buy rating for the company's stocks". ![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
